ARIAD Pharma (ARIA) Misses Q1 EPS by 2c

ARIAD Pharma (NASDAQ: ARIA) reported Q1 EPS of ($0.28), $0.02 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $23.9 million versus the consensus estimate of $27.26 million.

For earnings history and earnings-related data on ARIAD Pharma (ARIA) click here.

You May Also Be Interested In

• Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
• Mercury Systems (MRCY) Misses Q4 EPS by 2c
• Prenetics Global (PRE) Tops Q2 EPS by 18c